Top Story Today
$18.3 Billion and Counting: Biotech's Civil War Over China
U.S. pharma signed 14 licensing deals with Chinese companies worth a prospective total of about $18.3 billion by mid-2025, and Q1 2026 is on pace to double that. A sweeping STAT investigation reveals an industry tearing itself apart over whether this flood of deals is smart business or strategic suicide. One-third of new compounds entering U.S. pipelines now originate in Chinese labs, and projections suggest 35% of FDA approvals could come from China-developed drugs by 2040. The BIOSECURE Act is now law, but full enforcement won't hit until 2028, and finding alternative manufacturers could take up to eight years.
Why it matters: This isn't just a trade story; it's a structural reshaping of how drugs get discovered, manufactured, and brought to market globally. The outcome will determine whether Western pharma rebuilds domestic R&D capacity or locks itself into dependence on a geopolitical rival for the next generation of medicines.
Read more →Clinical Breakthroughs
The Drug Target Pharma Left for Dead Just Got a Second Life
PI3K inhibitors were oncology's biggest cautionary tale: multiple drugs pulled after patients on treatment actually died sooner than those without it. Now Relay Therapeutics is charging ahead with zovegalisib, a motion-designed molecule that selectively hits mutant PI3K while sparing healthy cells. It already has Breakthrough Therapy Designation in breast cancer, and Relay is pivoting into rare vascular diseases affecting an estimated 170,000 U.S. patients per year.
Read more →Two Companies, One Decades-Old Disease, Zero Cures
Since 1989, the best treatment for alpha-1 antitrypsin deficiency has been a weekly IV drip. Now Sanofi (via its $1.7 billion Inhibrx acquisition) and Wave Life Sciences are racing toward radically different fixes. Sanofi's protein replacement extends dosing to monthly; Wave's RNA editor corrects the genetic typo causing the disease, potentially treating both lung and liver damage from a single injection.
Read more →Deals & Strategy
Why Merck Is Lending Its Crown Jewel to a Rival's Trial
Merck will supply Keytruda (the world's $30 billion-a-year cancer drug) for Exelixis' Phase 3 head and neck cancer trial. With Keytruda's core patent expiring in 2028, Merck is stacking combination approvals to build a patent thicket that biosimilar makers can't easily copy. Exelixis keeps all commercial rights to its drug zanzalintinib, making this a low-cost, high-upside play for both sides.
Read more →China's Homegrown Obesity Pill Just Put Eli Lilly on Notice
While Lilly pours $3 billion into Chinese manufacturing, five-year-old Vincentage Pharma posted Phase 3 results showing 12.4% weight loss from a once-daily oral GLP-1 pill in 840 patients. The company plans to file for Chinese approval, targeting a market of over 500 million overweight adults. With only 1.8% of patients dropping out from side effects and no fasting requirements, VCT220 could become a serious local competitor.
Read more →Survival Mode
Quince Therapeutics Just Sold Itself for 7 Cents on the Dollar
After its only drug failed a Phase 3 trial and its stock sank below $1, Quince Therapeutics announced a reverse merger with private biotech Orphai Therapeutics. Existing Quince shareholders will own just 6.9% of the combined company. The deal comes with up to $187 million in new financing and gives Orphai a Nasdaq listing without a traditional IPO, adding to biotech's growing wave of last-resort reverse mergers.
Read more →